Do schizophrenia patients with low P50-suppression report more perceptual anomalies with the sensory gating inventory?

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 157-162

  Micoulaud Franchi, Jean Arthur ^a,b,c   Hetrick, William P ^d,e,f   Aramaki, Mitsuko ^g   Bolbecker, Amanda ^d,e,f   Boyer, Laurent ^a,h   Ystad, Sølvi ^g   Kronland Martinet, Richard ^g   Richieri, Raphaëlle ^a,h   Faget, Catherine ^a,h   Faugere, Mélanie ^a,b,c   El Kaim, Alexandre ^a,b,c   Cermolacce, Michel ^a,b,c   Lancon, Christophe ^a,h   Vion Dury, Jean ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c CNRS   (France)

^d INDIANA UNIVERSITY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Larue D Carter Memorial Hospital   (United States)

^g AIX MARSEILLE UNIVERSITY   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

Author keywords

P50; Perceptual anomalies; Schizophrenia; Self report; Sensory gating

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; P50 SUPPRESION; PERCEPTION DISORDER; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOPHRENIA; SCORING SYSTEM; SELF REPORT; SENSORY GATING; SENSORY GATING INVENTORY; SENSORY STIMULATION; STIMULUS RESPONSE; BRAIN; CHRONIC DISEASE; EVOKED RESPONSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; BRAIN; CHRONIC DISEASE; EVOKED POTENTIALS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF REPORT; SENSORY GATING;

EID: 84904100966     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.013     Document Type: Article

References (46)

1. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatry 1982, 17(6):639-654.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorder. Text Revision (DSM-IV-TR) 2000, American Psychiatric Association, Washington, DC. 4th ed.
3. Baker N., Adler L.E., Franks R.D., Waldo M., Berry S., Nagamoto H., Muckle A., Freedman R. Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses. Biol. Psychiatry 1987, 22(5):603-617.
4. Boutros N.N., Belger A. Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating. Biol. Psychiatry 1999, 45(7):917-922.
5. Brenner C.A., Kieffaber P.D., Clementz B.A., Johannesen J.K., Shekhar A., O'Donnell B.F., Hetrick W.P. Event-related potential abnormalities in schizophrenia: a failure to "gate in" salient information?. Schizophr. Res. 2009, 113(2-3):332-338.
6. Bunney W.E., Hetrick W.P., Bunney B.G., Patterson J.V., Jin Y., Potkin S.G., Sandman C.A. Structured Interview for Assessing Perceptual Anomalies (SIAPA). Schizophr. Bull. 1999, 25(3):577-592.
7. Cadenhead K.S., Light G.A., Geyer M.A., Braff D.L. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am. J. Psychiatry 2000, 157(1):55-59.
8. Cardenas V.A., Gerson J., Fein G. The reliability of P50 suppression as measured by the conditioning/testing ratio is vastly improved by dipole modeling. Biol. Psychiatry 1993, 33(5):335-344.
9. Cermolacce M., Micoulaud J.A., Naudin J., Vion-Dury J. Electrophysiology and schizophrenic vulnerability: The P300 component as endophenotype candidate?. Encéphale 2011, 37(5):353-360.
10. Clementz B.A., Geyer M.A., Braff D.L. P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol. Psychiatry 1997, 41(10):1035-1044.
11. Clementz B.A., Geyer M.A., Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr. Res. 1998, 30(1):71-80.
12. Davis J.M. Comparative doses and costs of antipsychotic medication. Arch. Gen. Psychiatry 1976, 33(7):858-861.
13. First R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders: Clinical Version (SCID-CV) 1997, American Psychiatric Press, Washington (DC).
14. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol. Psychiatry 1983, 18(5):537-551.
15. Freedman R., Adler L.E., Gerhardt G.A., Waldo M., Baker N., Rose G.M., Drebing C., Nagamoto H., Bickford-Wimer P., Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophr. Bull. 1987, 13(4):669-678.
16. Gjini K., Arfken C., Boutros N.N. Relationships between sensory "gating out" and sensory "gating in" of auditory evoked potentials in schizophrenia: a pilot study. Schizophr. Res. 2010, 121(1-3):139-145.
17. Guy W. Clinical global impression. Assessment manual for psychopathology 1976, (revised, MD, Rockville). ECDU (Ed.).
18. Hetrick W.P., Erickson M.A., Smith D.A. Phenomenological dimensions of sensory gating. Schizophr. Bull. 2012, 38(1):178-191.
19. Jin Y., Bunney W.E., Sandman C.A., Patterson J.V., Fleming K., Moenter J.R., Kalali A.H., Hetrick W.P., Potkin S.G. Is P50 suppression a measure of sensory gating in schizophrenia?. Biol. Psychiatry 1998, 43(12):873-878.
20. Johannesen J.K., Bodkins M., O'Donnell B.F., Shekhar A., Hetrick W.P. Perceptual anomalies in schizophrenia co-occur with selective impairments in the gamma frequency component of midlatency auditory ERPs. J. Abnorm. Psychol. 2008, 117(1):106-118.
21. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
22. Kisley M.A., Noecker T.L., Guinther P.M. Comparison of sensory gating to mismatch negativity and self-reported perceptual phenomena in healthy adults. Psychophysiology 2004, 41(4):604-612.
23. Lancon C., Aghababian V., Llorca P.M., Auquier P. Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five-dimensional factor analysis. Acta Psychiatr. Scand. 1998, 98(5):369-376.
24. Lancon C., Auquier P., Reine G., Toumi M., Addington D. Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale. Psychiatry Res. 1999, 89(2):123-132.
25. Light G.A., Braff D.L. Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients?. Biol. Psychiatry 2000, 47(5):463-467.
26. Light G.A., Braff D. Sensory gating deficits in schizophrenia: can we parse the effects of medication, nicotine use, and changes in clinical status. Clin. Neurosci. Res. 2003, 3(1):47-54.
27. McGhie A., Chapman J. Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 1961, 34:103-116.
28. McKenna S. Measuring quality of life in schizophrenia. Eur. Psychiatry 1997, 12(3):267s-274s.
29. Micoulaud Franchi J.A., Vion Dury J., Cermolacce M. Neurophysiological endophenotypes and schizophrenic disorder: emergence and evolution of a clinical concept. Encéphale 2013, 38(Suppl. 3):S103-S109.
30. Micoulaud-Franchi J.A., Vion-Dury J. What is sensory inundation in schizophrenia?. Clin. Neurophysiol. 2013, 124(3):628-629.
31. Micoulaud-Franchi J.A., Aramaki M., Merer A., Cermolacce M., Ystad S., Kronland-Martinet R., Naudin J., Vion-Dury J. Toward an exploration of feeling of strangeness in schizophrenia: perspectives on acousmatic and everyday listening. J. Abnorm. Psychol. 2012, 121(3):628-640.
32. Micoulaud-Franchi J.A., Hetrick W.P., Boyer L., Aramaki M., Ystad S., Richieri R., El-Kaim A., Faget C., Faugere M., Cermolacce M., Kronland-Martinet R., Lançon C., Vion-dury J. Validation of the French sensory gating inventory: a confirmatory factor analysis 2014, (submitted for publication, in revision).
33. Nagamoto H.T., Adler L.E., Waldo M.C., Freedman R. Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol. Psychiatry 1989, 25(5):549-561.
34. Nagamoto H.T., Adler L.E., Waldo M.C., Griffith J., Freedman R. Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schizophr. Res. 1991, 4(1):31-40.
35. Nagamoto H.T., Adler L.E., McRae K.A., Huettl P., Cawthra E., Gerhardt G., Hea R., Griffith J. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 1999, 39(1):10-17.
36. Nunnally J., Bernstein I. Psychometric theory 1994, McGraw-Hill, New York. third ed.
37. Patterson J.V., Sandman C.A., Jin Y., Kemp A.S., Potkin S.G., Bunney W.E. Gating of a novel brain potential is associated with perceptual anomalies in bipolar disorder. Bipolar Disord. 2013, 15(3):314-325.
38. Sanchez-Morla E.M., Santos J.L., Aparicio A., Garcia-Jimenez M.A., Soria C., Arango C. Neuropsychological correlates of P50 sensory gating in patients with schizophrenia. Schizophr. Res. 2013, 143(1):102-106.
39. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. (quiz 34-57).
40. Slevin M.L., Plant H., Lynch D., Drinkwater J., Gregory W.M. Who should measure quality of life, the doctor or the patient?. Br. J. Cancer 1988, 57(1):109-112.
41. Spielberger C.D., Vagg P.R. Psychometric properties of the STAI: a reply to Ramanaiah, Franzen, and Schill. J. Pers. Assess. 1984, 48(1):95-97.
42. Uhlhaas P.J., Mishara A.L. Perceptual anomalies in schizophrenia: integrating phenomenology and cognitive neuroscience. Schizophr. Bull. 2007, 33(1):142-156.
43. White P.M., Yee C.M. Effects of attentional and stressor manipulations on the P50 gating response. Psychophysiology 1997, 34(6):703-711.
44. White P.M., Kanazawa A., Yee C.M. Gender and suppression of mid-latency ERP components during stress. Psychophysiology 2005, 42(6):720-725.
45. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
46. Yee C.M., Williams T.J., White P.M., Nuechterlein K.H., Ames D., Subotnik K.L. Attentional modulation of the P50 suppression deficit in recent-onset and chronic schizophrenia. J. Abnorm. Psychol. 2010, 119(1):31-39.